A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings

British Journal of Cancer

Volumn 104, Issue 3, 2011, Pages 407-412

  Okera, M ^a   Chan, S ^a   Dernede, U ^b   Larkin, J ^c   Popat, S ^c   Gilbert, D ^c   Jones, L ^d   Osuji, N ^e   Sykes, H ^f   Oakley, C ^a   Pickering, L ^b   Lofts, F ^b   Chowdhury, S ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^f KINGSTON HOSPITAL   (United Kingdom)

Author keywords

chemotherapy; febrile neutropenia; infection; neutropenic sepsis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 79551609201     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6606059     Document Type: Article

References (32)

1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433-2453
2. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, Garcia-Garre E, Martin P, Bosch A, Lluch A (2006) Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 24, No 18S (June 20 Supplement), 2006: 668
3. Clamp AR, Ryder WD, Bhattacharya S, Pettengell R, Radford JA (2008) Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin0s lymphoma. Br J Cancer 99: 253-258
4. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B (2005) Colonystimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23: 4198-4214
5. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100: 228-237
6. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353: 988-998
7. Cullen MH, Billingham LJ, Gaunt CH, Steven NM (2007) Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 25: 4821-4828
8. Dale D, McCarter G, Crawford J, Lyman G (2003) Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Cancer Netw 1: 440-454
9. Dikken C (2009) Raising awareness educating non-specialist staff about neutopenic sepsis. Macmillan Voice Spring Practice Supplement, a-h
10. Engels EA, Lau J, Barza M (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16: 1179-1187
11. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA (1999) A doubleblind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341: 305-311
12. Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142(12 Part 1): 979-995
13. Goossens H, Ferech M, Vander Stichele R, Elseviers M (2005) Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365: 579-587
14. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751
15. Innes H, Billingham L, Gaunt C, Steven N, Marshall E (2005) Management of febrile neutropenia in the United Kingdom: time for a national trial? Br J Cancer 93: 1324-1328
16. Innes HE, Smith DB, OReilly SM, Clark PI, Kelly V, Marshall E (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 89: 43-49
17. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341: 312-318
18. Klastersky J, Paesmans M (2007) Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Support Care Cancer 15: 477-482
19. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258-2266
20. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25: 3158-3167
21. Lyman GH (2005) Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 3: 557-571
22. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkins lymphoma: a nationwide study. J Clin Oncol 22: 4302-4311
23. Lyman GH, Kuderer N, Greene J, Balducci L (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34: 1857-1864
24. NCAG (2009) Chemotherapy Services in England: Ensuring Quality, Safety: A Report from the National Chemotherapy Advisory Group. National Chemotherapy Advisory Group: UK.
25. NCCN (2009) Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. V.1.2009. National Comprehensive Cancer Network: USA
26. NCCN (2008) Clinical Practice Guidelines in Oncology: Prevention, Treatment of Cancer-Related Infections. V.1.2008. National Comprehensive Cancer Network: USA
27. NCEPOD (2008) For better, for worse? A review of the care of patients who died within 30 days of receiving systemic anti-cancer therapy. National Confidential Enquiry into Patient Outcome, Death: UK.
28. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkins lymphoma: a randomized controlled trial. Blood 80: 1430-1436
29. Pietropaolo M, Gianni W, Siliscavalli A, Marigliano V, Repetto L (2003) The use of colony stimulating factors in elderly patients with cancer. Crit Rev Oncol Hematol 48: S33-S37
30. Repetto L, Biganzoli L, Koehne CH, Luebbe AS, Soubeyran P, Tjan-Heijnen VC, Aapro MS (2003) EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39: 2264-2272
31. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: 3187-3205
32. Vidal L, Ben-Dor I, Paul M, Pokroy E, Soares-Weiser K, Leibovici L (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev (4): CD003992